Antibiotics are losing efficacy due to the rapid evolution and spread of resistance. 18
Introduction 41
Scientists together with the World Health Organization (WHO) forecast that the rapid 42 evolution and spread of antibiotic resistant bacteria will lead to a world-wide medical 43 crisis [1] [2] [3] . Already today, the effective treatment of an increasing number of 44 infectious diseases has become difficult in many cases [4, 5] . To avert the crisis, 45 novel innovative approaches that are both effective against pathogens and robust to 46 the emergence and spread of resistance are urgently needed [6, 7] . One such 47 approach involves the use of compounds that disarm rather than kill bacteria. These 48 so-called 'antivirulence' treatments should exert weaker selection for resistance 49 compared to classical antibiotics because they simply disable virulence factors but 50 are not supposed to affect pathogen viability [8] [9] [10] . However, a downside of 51 antivirulence approaches is that the infection will not necessarily be cleared. This 52 could be particularly problematic for immuno-compromised patients (AIDS, cancer, 53 cystic fibrosis and intensive-care unit patients), whose immune system is conceivably 54 too weak to clear even disarmed pathogens. 55 56 One way to circumvent this problem is to combine antivirulence compounds with 57 antibiotics to benefit from both virulence suppression and effective pathogen removal 58 6 virulence factors are important for growth ( Figure 2) . Crucially, the dose-response 115 curves shifted to the right (extending phase (i)) when we repeated the experiment in 116 media, where the virulence factors are not needed for growth (i.e. iron-rich media for 117 pyoverdine, and protein digest media for proteases). This shows that there is a 118 window of concentrations where growth inhibition is caused by virulence factor 119 quenching alone. Conversely, high concentrations of antivirulence compounds seem 120 to have additional off-target effects curbing growth. 121 122
Interaction maps of antibiotic-antivirulence drug combinations 123
General patterns. From the dose-response curves, we chose 9 concentrations for 124 each drug to cover the entire trajectory, from no to intermediate to high growth 125
inhibition. We then combined antibiotics with antivirulence compounds in a 9x9 126 concentration matrix and measured the dose-response curve for every single drug 127 combination for both growth and virulence factor production ( Figure 3 ). At the 128 qualitative level, independent drug effects would cause a symmetrical downshift of 129 (Figures 4A+B) . With regard to the inhibition of pyoverdine production, both drug 140 combinations showed a tendency towards stronger synergy at intermediate drug 141
concentrations ( Figure 4E+F ). For gallium-meropenem combinations, we observed 142 mostly independent interactions for growth and pyoverdine inhibition, with small 143 hotspots of antagonism (for growth) and synergy (for siderophore inhibition) existing 144 at intermediate drug concentrations (Figure 4C+G ). Finally, for gallium-tobramycin 145 combinations there were relatively strong synergistic interactions for both growth 146 ( Figure 4D ) and pyoverdine inhibition ( Figure 4H relatively strong antagonistic interactions with regard to growth inhibition ( Figure 4I) , 151
whereas effects on protease inhibition were mostly independent ( Figure 4M ). In 152 contrast, for furanone-colistin combinations we observed strong synergistic drug 153 interactions especially for intermediate and higher concentrations of the antivirulence 154 compound for growth and protease inhibition ( Figure 4J+N ). Furanone-meropenem, 155 on the other hand, interacted mostly antagonistically with regard to growth and 156 protease inhibition ( Figure 4K+O ). Conversely, for furanone-tobramycin combinations correlations for ciprofloxacin and meropenem, but positive associations for colistin 165 and tobramycin (Pearson correlation coefficient; ciprofloxacin: r = 0.09, t79 = 0.85, p = 166 0.394; colistin: r = 0.69, t79 = 8.51, p < 0.001; meropenem: r = 0.17, t79 = 1.53, p = 167 0.130; tobramycin: r = 0.58, t79 = 6.39, p < 0.001). For furanone-antibiotic 168 combinations, there were strong positive correlations between the levels of synergy 169 for the two traits for all drug combinations (ciprofloxacin: r = 0.34, t79 = 3.22, p = 170 0.002; colistin: r = 0.96, t79 = 32.50, p < 0.001; meropenem: r = 0.87, t79 = 15.48, p < 171 0.001; tobramycin: r = 0.75, t79 = 10.16, p < 0.001). 172 173 Antivirulence compounds can restore growth inhibition of antibiotic resistant 174 strains 175
In a next step, we asked whether antivirulence compounds could be used as 176 adjuvants to suppress the growth of antibiotic resistant clones. To address this 177 question, we first experimentally selected and isolated antibiotic resistant clones 178 (AtbR, see methods for details). We then subjected these AtbR clones to antibiotic 179 and combinatorial treatments and compared their growth relative to the ancestral 180 antibiotic-sensitive wildtype. As expected, AtbR clones grew better than the wildtype 181 under antibiotic treatment alone (two-sample t-tests, -25.9 ≤ t7-16 ≤ -2.27, p < 0.05 for 182 all treatments). When adding anti-virulence compounds to the antibiotics, we found 183 that growth inhibition of the AtbR clones was restored in seven out of eight drug 184 combinations ( Figure 5A ). Overall, there were four different inhibition patterns: the 185 addition of antivirulence compounds either (i) did not affect the growth of the 186 antibiotic resistant strain (one case: ciprofloxacin-furanone); (ii) only fully restored 187 growth inhibition at higher anti-virulence compound concentration (five cases: all four but not high anti-virulence compound concentration (one case: meropenem-190 furanone); or (iv) inhibited growth more than in the antibiotic sensitive wildtype (one 191 case: tobramycin-furanone). 192
193

Specific drug combinations can reverse selection for antibiotic resistance 194
We then investigated whether the addition of an antivirulence compound to an 195 antibiotic treatment can influence the spread of AtbR clones in populations of 196 susceptible cells ( Figure 5B ). Our competition assays revealed that AtbR clones lost 197 against the susceptible wildtype in the absence of antibiotics, confirming that 198 antibiotic resistance is costly (one sample t-tests, -54.16 ≤ t7 ≤ -2.36, p ≤ 0.050 for all 199 comparisons). Conversely, AtbR clones always experienced a significant fitness 200 advantage compared to the wildtype under antibiotic treatment (one sample t-test, 201
3.05 ≤ t7 ≤ 12.80, p < 0.01 for all combinations). The addition of antivirulence 202 compounds to the antibiotic treatment had variable and combination-specific effects 203 on the fitness of AtbR clones, which included: (i) three cases where anti-virulence 204 compound addition did not affect the fitness advantage of the AtbR clones 205 (ciprofloxacin-gallium, ciprofloxacin-furanone and colistin-furanone); (ii) two cases 206
where the antivirulence adjuvant further potentiated the spread of AtbR clones 207 (colistin-gallium and meropenem-furanone); and (iii) three cases where the adjuvant 208 reversed selection for antibiotic resistance and thereby hindered the spread of AtbR 209 clones (meropenem-gallium, tobramycin-gallium and tobramycin-furanone). Detailed 210 information on statistical analysis for Figure 5B is reported in Supplementary Table  211 S1. 212
213
Drug synergy does not predict selection against antibiotic resistance 214
We examined whether drug interactions, ranging from antagonism to synergy ( Figure  215 4) correlate with the relative fitness of the AtbR clones in competition with the 216 antibiotic sensitive wildtype. However, we found no support for such associations 217 (Supplementary Figure S2 , ANOVA, growth: F1,48 = 0.65, p = 0.422; virulence factor: 218 F1,48 = 3.10, p = 0.082), but instead observed that variation in fitness patterns was 219 explained by specific drug combinations (antivirulence-antibiotic interaction: F3,48 = 220 15.76, p < 0.0001). 221
222
Genetic bases of experimentally evolved antibiotic resistance 223
The whole-genome sequencing of the experimentally evolved AtbR clones revealed 224 a small number of SNPs and INDELs, which are known to be associated with 225 resistance to the respective antibiotics ( Table 1) In this study, we systematically explored the effects of combining antibiotics with 252 antivirulence compounds as a potentially promising strategy to fight susceptible and 253 antibiotic resistant opportunistic human pathogens. Specifically, we combined four 254 different antibiotics (ciprofloxacin, colistin, meropenem, tobramycin) with two 255 antivirulence compounds (gallium targeting siderophore-mediated iron uptake and 256 furanone C-30 targeting the quorum sensing communication system) in 9x9 drug 257 interaction matrices against the bacterium P. aeruginosa as a model pathogen. Our 258 heat maps reveal drug-combination specific interaction patterns. While colistin and 259 tobramycin primarily interacted synergistically with the antivirulence compounds, 260 independent and antagonistic interactions occurred for ciprofloxacin and meropenem 261 in combination with the antivirulence compounds (Figures 3+4). We then used 262 antivirulence compounds as adjuvants and observed that they can restore growth 263 inhibition of antibiotic resistant clones in seven out of eight cases ( Figure 5A ). Finally, we performed competition assays between antibiotic resistant and susceptible strains 265 under single and combinatorial drug treatments and found that antivirulence 266 compounds can reverse selection for antibiotic resistance in three out of eight cases 267 ( Figure 5B ). Our results identify antibiotic-antivirulence combinations as a potentially remove the antagonistic effect on the second drug, such that the combination 296 treatment will be more effective against the resistant clones [52]. We suspected that 297 such effects might also occur for antagonistic antibiotic-antivirulence treatments. 298
While we indeed observed that combination therapy can reverse selection for 299 resistance in certain cases ( Figure 5B ), there was no evidence that this effect 300 correlated with the type of drug interaction (Supplementary Figure S2) . A possible 301 explanation for the lack of any association is that the antagonism between antibiotics 302 and antivirulence compounds was quite moderate. In contrast, previous work used 303 an extreme case of antagonism, where the effect of one drug was almost completely 304 suppressed in the presence of the second drug [52, 54] . 305
306
We propose that it is rather the underlying molecular mechanism and not the 307 direction of drug interaction that determines whether selection for antibiotic 308 resistance is reversed or potentiated. For instance, any resistance mechanism that 309 reduces antibiotic entry or increases its efflux could conceivably induce cross-310 resistance to antivirulence compounds, which should in turn potentiate and not 311 reverse selection for antibiotic resistance. This phenomenon could explain the efflux pumps, porins and membrane lipopolysaccharide modifications (Table 1) . 315
Since furanone needs to enter the cells to become active, these mutations, known to 316 confer resistance to antibiotics [37,38,41], likely also induce resistance to furanone 317 used for competition assays were generated through experimental evolution and are 372 listed in Table 1 Table S2 ). We then combined these drug concentrations in a 9x9 431 matrix for each of the eight antibiotic-antivirulence pairs, and repeated the growth 432 experiment for all combinations in six-fold replication, exactly as described above. 433
After 48 hours of incubation, we measured growth and virulence factor production 434 following the protocols described above. To select for antibiotic resistant clones, we exposed overnight cultures of PAO1 449 wildtype (initial OD600 = 10 -4 ) to each of the four antibiotics in LB medium (antibiotic 450 concentrations, ciprofloxacin: 0.15 μg/ml; colistin: 0.5 μg/ml; meropenem: 0.8 μg/ml; 451 tobramycin: 1 μg/ml) in six-fold replication. These antibiotic concentrations initially 452 caused a 70-90% reduction in PAO1 growth compared to untreated cultures, 453 conditions that imposed strong selection for the evolution of resistance. The evolution 454 experiment ran for seven days, whereby we diluted bacterial cultures and transferred 455 them to fresh medium with the respective treatment with a dilution factor of 10 -4 , 456 every 24 hours. At the end of each growth cycle, we measured growth (OD600) of the 457 evolving lineages using a SpectraMax® Plus 384 plate reader (Molecular Devices, 458 Switzerland). 459
Following experimental evolution, we screened the evolved lines for the presence of 462 antibiotic resistant clones. For each antibiotic we plated four evolved lines on LB 463 plates and isolated single clones, which we then exposed in liquid culture to the 464 antibiotic concentration they experienced during experimental evolution. Among 465 those that showed growth restoration (compared to the untreated wildtype), we 466 picked two random clones originating from different lineages per antibiotic for further 467 analysis. We had to adjust our sampling design in two cases. First, only one 468 population survived our ciprofloxacin treatment and thus only one resistant clone 469 could be picked for this antibiotic. Second, clones evolved under colistin treatment 470 grew very poorly in CAS medium and therefore we included an experimentally 471 evolved colistin resistant clone from a previous study, which did not show 472 compromised growth in CAS (see [73] for a description on the experimental 473 evolution). Altogether, we had seven clones for which we re-established the drug-474 response curves (Supplementary Figure S6 
Competition experiments between sensitive and resistant clones 495
To examine the conditions under which antibiotic resistant clones can spread, we 496 competed the sensitive wildtype PAO1 (tagged with GFP) against the experimentally 497 evolved antibiotic resistant clones (Table 1) the Supplementary Table S3 , while antivirulence concentrations were as follows, 501 gallium: 1.56 μM (low), 6.25 μM (medium), 12.5 μM (high); furanone: 6.3 μM (low), 502 22.8 μM (medium), 51.4 μM (high). Bacterial overnight cultures were prepared and 503 diluted as described above. Competitions were initiated with a mixture of 90% 504 sensitive wildtype cells and 10% resistant clones to mimic a situation where 505 resistance is still relatively rare. Mixes alongside with monocultures of all strains were 506 inoculated in either 200 μl of CAA+Tf or CAS under all the five treatment regimes. 507
We used flow cytometry to assess strain frequency prior and after a 24 hours 508 competition period at 37°C static (Supplementary Figure S7) . Specifically, bacterial 509 cultures were diluted in 1X phosphate buffer saline (PBS, Gibco, ThermoFisher, side and forward scatter: 200 V threshold; events recorded with CS&T settings) at 513 the Cytometry Facility of the University of Zurich. We recorded 50'000 events before 514 competitions and used a high-throughput sampler device (BD Bioscience) to record 515 all events in a 5 μl-volume after competition. Since antibacterials can kill and thereby 516 quench the GFP signal in tagged cells, we quantified dead cells using the propidium 517 iodide (PI) stain (2 μl of 0.5 mg/ml solution) with flow cytometry (for PI fluorescence: 518 laser: 561 nm, mirror: 600LP, filter: 610/20). 519 520
We used the software FlowJo (BD Bioscience) to analyse data from flow cytometry 521 experiments. We followed a three-step gating strategy: (i) we separated bacterial 522 cells from media and noise background by using forward and side scatter values as a 523 proxy for particle size; (ii) within this gate, we then distinguished live from dead cells 524 tag, we included a control competition, where we mixed PAO1-GFP with the 534 untagged PAO1 in a 9:1 ratio for all treatment conditions. We noted that high drug events that could be measured with flow cytometry. This growth reduction increased 537 noise relative to the signal, leading to an overestimation of the GFP-negative 538 population in the mix. To correct for this artefact, we established calibration curves 539 (described by asymptotic functions, Supplementary Table S2) populations (growth and virulence factor production). We exposed PAO1 to the 876 antivirulence compounds gallium (inhibiting pyoverdine-mediated iron uptake) and 877 furanone C-30 (blocking quorum sensing response including protease production) both 878 in media where the targeted virulence factors are expressed and required (iron-limited 879
CAA+Tf medium for gallium and CAS medium for furanone) and in control media 880
where the targeted virulence factors are not required (iron-supplemented CAA+Fe 881 medium for gallium and protein digested CAA for furanone). (A) Dose-response curves 882 for growth show that both antivirulence compounds reduced bacterial growth, but more 883 so in media where the targeted virulence factor is expressed. This demonstrates that 884 there is a concentration window where the antivirulence compounds have no toxic 885 effects on bacterial cells and just limit growth due to virulence factor quenching. (B) 886
Dose-response curves for virulence factor production show that gallium and furanone 887 C-30 effectively inhibit pyoverdine and protease production, respectively, in a 888 concentration-dependent manner. Dots show means ± standard errors across six 889
replicates. All data are scaled relative to the drug-free treatment. Data stem from two 890 independent experiments using different dilution series. The red dots indicate the 891 highest concentration used for the respective experiments, from which 7-serial dilution 892 steps were tested. Curves were fitted with either log-logistic functions (in CAA+Tf) or 893 with three-parameter Weibull functions (in CAS). The antibiotic resistant strains are referred to as AtbR throughout the text. 
